Clinical trial · Interventional

A Study Evaluating a New Radiation Treatment Workflow (NGDS)

A ProSPEctivE Study of NGDS DMAT Workflow Feasibility

NCT07824583CI-TRIAL-00126414SPEEDrecruitingN/AClinicalTrials.gov clinicaltrialsPublishedExplore in graph →

Summary

Brief summary (as posted)

The purpose of this research is to evaluate the "Next Generation Delivery System" (NGDS) and determine if this machine will be more efficient at delivering radiation in shorter treatment time and better patient tolerance, with less breath holding.

Conditions

Conditions (5)

Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.

Condition (as posted)	Mapped entity	Match	Confidence
Abdominal Cancer	Malignant Abdominal Neoplasm	ALIAS	0.90
Liver Cancer, Adult	Hepatocellular Carcinoma	ALIAS	0.90
Lung Cancer (Diagnosis)	Malignant Lung Neoplasm	CURATED_EXACT	0.85
Pancreatic Cancer	Malignant Pancreatic Neoplasm	CURATED_EXACT	0.92
Thoracic Cancers	Malignant Thoracic Neoplasm	ALIAS	0.90

Interventions

Interventions (1)

Intervention	Type	Mapped drug	Match
Next Generation Delivery System (NGDS)	Device	—	UNRESOLVED

Design

Arms and outcomes

Arms (1)

type
OTHER
label
Single Arm - All patients will be treated the same
description
"Mock" treatment on the NGDS machine.
interventionNames
1. Device: Next Generation Delivery System (NGDS)

Primary outcomes (1)

measure
To evaluate the feasibility of the mock NGDS DMAT workflow under breath hold conditions.
timeFrame
From enrollment to end of "mock" treatment of last participant enrolled, assessed up to 6 months
description
Feasibility of the mock NGDS DMAT treatment workflow under breath hold conditions will be confirmed following successful execution of each step: 1. Acquisition of an IDENTIFY-monitored breath hold kV HyperSight CBCT 2. Conduct verification imaging of shifts and breath hold position using kV fluoroscopy 3. Delivery of an investigator approved "mock" DMAT treatment plan

Secondary outcomes (6)

measure

Eligibility

Eligibility (as posted)

Sex: All
Minimum age: 21 Years

Show eligibility criteria text

Inclusion Criteria:

1. Target lesions in the thorax or upper abdomen
2. Planned to undergo SBRT radiation treatment delivered on a conventional "C-arm" or ring gantry CBCT guided linear accelerator under breath hold conditions
3. ECOG performance status 0-1
4. At least 21 years of age
5. Able to sign informed consent

Exclusion Criteria:

1. Participants enrolled in another clinical investigation the investigator believes to be in conflict with this clinical investigation.
2. Participants with any other medical condition or laboratory value that would, at the discretion of the investigator, preclude the patient from participation in this clinical investigation.

References

Publications (0)

Data not yet available

No reference posted for this study.

Registry

Dates and enrollment

Start: Jul 31, 2026
Primary completion: Feb 1, 2027
Completion: May 1, 2027
First posted: Sep 17, 2026
Last update posted: Sep 17, 2026
Enrollment: 20 (estimated)
Lead sponsor: Varian, a Siemens Healthineers Company INDUSTRY
Keywords: Stereotactic body radiation therapy, Lung cancer, Liver cancer, Pancreatic cancer, Thoracic cancer, abdominal cancer, Breath hold, DMAT, linac, motion monitoring, linear accelerator, kV fluoroscopy, C-arm

Data updated 12 days agoSource updated Sep 17, 2026source: clinicaltrials

Locations

Locations by country (2)

Country	Sites	Recruiting
United States	2	2

Trial listing is informational. Eligibility is decided by the study team; contact information is on ClinicalTrials.gov.